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ABSTRACT 
At present 40% of the drugs within the development pipelines, and approximately 60 % of the drugs coming directly from synthesis 
area unit poorly soluble.  Solubility is one of the important parameter to obtain desired concentration of drug in systemic circulation. 
Liquisolid compacts technique is a new and promising approach to overcome this consequence and that can change the dissolution 
rate of water insoluble drugs and increase the bioavailability of the drugs. This technique is an efficient method for formulating 
water insoluble and water soluble drugs. This technique relies upon the admixture of drug loaded solutions with applicable carrier 
and coating materials. Liquisolid system is characterized by flow behaviour, wettability, powder bed hydrophilicity, saturation 
solubility, drug content, differential scanning calorimetry, Fourier transform infra-red spectroscopy, powder X-ray diffraction, 
scanning electron microscopy, in-vitro release and in-vivo evaluation. This review article explains the preparation, classification and 
application of liquisolid system.   
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INTRODUCTION 
The oral route is the most preferred route of drug 
administration due to the ease, high patient acceptance, 
and low cost production. The drug must be presented in 
solution form for absorption through gastrointestinal 
tract (GIT) when given orally.The solubility and 
dissolution behaviour of a drug is the key determinants 
of its oral Bioavailability 
1
. Release improvement of 
poorly soluble drugs is rise achieved by a rise of the 
drug surface area, the drug solubility, or by formulating 
the drug in its dissolved state. Numerous 
techniques are used to formulate oral drug delivery 
system that might enhance the dissolution profile 
and successively, the absorption potency of water 
insoluble drugs likes micronization, adsorption onto high 
surface area transporters, lyophilization, co-grinding, 
formulation of inclusion complexes, solubilization by 
surfactants, solid dispersions, solid solutions, 
hydrotrophy, inclusion of the drug resolution or liquid 
drug into soft gelatin capsules, and cosolvency and 
liquisolid compact technology
2
. The Liquisolid compact 
concept described by Spireas et. al. in this system oily 
liquid drug and solution or suspension of water insoluble 
drug in to non-volatile solvent 
3
. Liquisolid technology, 
a liquid is also reworked into a free flowing, without 
delay compressible and apparently dry powder by easy 
physical mixing with elect excipients named the carrier 
and coating material. The liquid portion, which can be a 
liquid drug, a drug suspension or a drug solution in to 
suitable non-volatile liquid vehicles, is combined into 
the carrier material. The foremost promising and new 
technique for supporting dissolution is that the formation 
of liquisolid tablets among the numerous novel 
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techniques. Liquisolid compacts promotes dissolution 
rate of water insoluble drugs to a greater extent and 
additionally enhances the drug flow property 
4, 5
. 
 
Fig. 1: Schematic representation of liquisolid system. 
CLASSIFICATION 
A. Based on the liquid medication, it divided into three 
sub groups:  
1. Powdered drug solutions  
2. Powdered drug suspensions 
 3. Powdered liquid drug 
The major two is also made from the conversion of drug 
solutions or drug suspensions (e.g. gemfibrozil 
suspension in Polysorbate 80), and therefore the 
formulation of liquid drugs (e.g. clofibrate, valproic 
acid, liquid vitamins, etc.), into liquisolid systems.  
B. Based on the formulation technique, liquisolid 
systems is classified into two groups, 
1. Liquisolid compacts: It refers to immediate sustained 
release tablets or capsules that are described under 
liquisolid systems. 
2. Liquisolid microsystems: It refers to capsules ready 
by liquisolid systems with the inclusion of an additive 
resultant in a unit size that may be as much as five times 
less than that of a liquisolid compact 
6
.  
Theory of Liquid Solid Systems: 
A powder can retain only restricted amounts of liquid 
whereas maintaining acceptable flow and compression 
properties. To calculate the essential amounts of powder 
excipients (carrier and coating materials) a mathematical 
approach for the formulation of liquisolid systems has 
been developed by Spireas. This approach is predicated 
on the flowable (Ф value) and compressible (Ψ-number) 
liquid retention potential introducing constants for each 
powder/liquid combination. The Ф-value of a powder 
represents the determined amount of a given non-volatile 
liquid which will be maintained within its bulk [w/w] 
whereas maintaining asuitable flowability. The 
flowability may be determined from the powder flow or 
by measurement of the angle of repose 
7
. 
The Ψ-number of a powder is defined as the maximum 
amount of liquid the powder can retain inside its bulk 
[w/w] while maintaining acceptable compactability 
resulting in compacts of sufficient hardness with no 
liquid permeable out throughout compression. 
 The compactability determined by the pactisity, which 
describes the maximum (plateau) crushing strength of a 
one-gram tablet compacted at sufficiently high 
compression forces. 
The terms “acceptable flow and compression properties” 
imply the specified so preselected flow and compaction 
properties that has to to be met by the ultimate word 
liquisolid formulation. 
Depending on the excipient ratio (R) of the powder 
substrate an reasonably flowing and compressible 
liquisolid system can be obtained only if a maximum 
liquid load on the carrier material is not exceeded. This 
liquid/carrier ratio is termed “liquid load factor Lf“ 
[w/w] and is defined as the weight ratio of the liquid 
formulation (W) and the carrier material (Q) in the 
system:  
Lf =W /Q                Eq. (1) 
R represents the quantitative relation between the 
weights of the carrier (Q) and also the coating (q) 
material gift within the formulation: 
R=Q/q                      Eq. (2) 
 The liquid load factor that ensures acceptable 
flowability (ΦLf ) can be determined by:  
ΦLf = Φ +φ⋅(1/R)      Eq. (3) 
where Φ and φ are the Ф-values of the carrier and 
coating material, respectively. Similarly, the liquid ratio 
for production of liquisolid systems with acceptable 
compactability (ΨLf ) is decided by: 
ΨLf = Ψ +ψ⋅(1/R)           Eq. (4) 
where Ψ and ψ are the Ψ-numbers of the carrier and 
coating material, respectively.In Table-1 sample of 
liquisolid formulation parameters of different powder 
excipients with usuallyused liquid vehicles are listed. 
Therefore, the optimum liquid load factor (Lo) needed to 
get tolerably flowing and compressible liquisolid 
systems are adequate to either ΦLforΨLf, whichever 
represents the lower value. 
As soon as the optimum liquid load factor is determined, 
the appropriatequantities of carrier (Qo) and coating (qo) 
material required to convert a given amount of liquid 
formulation (W) into an acceptably flowing and 
compressible liquisolid system is additionally calculated 
as follows: 
Q0 = W/Lo----- (5) 
And   q0 = Q0/R------- (6) 
 
Pawar et al                                                                                                                Journal of Drug Delivery & Therapeutics. 2017; 7(4):6-11                                  
ISSN: 2250-1177                                                                              [8]                                                                            CODEN (USA): JDDTAO 
Table 1: Liquisolid formulation parameters of various powder excipients with commonly used liquid vehicles 
Powder Excipient or System Ф-values Ψ-numbers 
Propylene glycol PEG 400 Propylene glycol PEG 400 
Avicel pH 102 0.16 0.005 0.224 0.242 
Avicel pH 200 0.26 0.02 0.209 0.232 
Cab-O-Sil M5 M5(silica)* With Avicel pH 102 3.31 3.26 0.560 0.653 
Cab OSilM5(silica)* With Avicel pH 200 2.57 2.44 0.712 0.717 
 
The validity and applicability of the above mentioned principles have been tested and verified by producing liquisolid 
compacts possessing acceptable flow and compaction properties 
8,9
. 
 
MECHANISMS OF ENHANCED DRUG 
RELEASE FROM LIQUISOLID SYSTEMS 
Several mechanisms of increased drug release have been 
proposed for liquisolid systems. The three main 
mechanisms include increased surface area of drug, 
increased aqueous solubility of the drug, and improved 
wettability of the drug particles. Formation of a complex 
between the drug and excipients or any changes in 
crystalline of the drug could be ruled out using DSC and 
XRPD measurements. 
a) Increased Aqueous Solubility   
b) Increased Drug Surface Area  
c) Increased Wettability   
a) Increased Drug Surface Area   
If the drug within the liquisolid system is totally 
dissolved within the liquid vehicle it is situated in the 
powder substrate still in a solubilized, molecularly 
spread state. Therefore, the surface area of drug 
available for release is way larger than that of drug 
particles inside directly compressed tablets. 
Accordingly, with increasing drug content surpassing 
thesolubility limit and so, increasing fraction of 
undissolved drug within the liquid vehicle the discharge 
rate decreases 
10
. 
b) Increased Aqueous Solubility of the Drug  
In addition to the primary mechanism of drug release 
improvement it is expected that cs, the solubility of the 
drug might be increase with liquisolid system. In fact 
the relatively small amount of liquid vehicle in a 
liquisolid compact is not adequate to extend the general 
solubility of the drug within the binary compound 
dissolution medium. However at the solid liquid 
interface between an distinct liquisolid primary particles 
and the release medium it is promising that in this micro 
environment the quantity of liquid vehicle spreading out 
of a single liquisolid particle together with the drug 
molecules might be adequate to extend the aqueous 
solubility of the drug if the liquid vehicle acts as co 
solvent 
11
. 
c) Increased Wettability   
Due to the very fact that the liquid vehicle will either act 
as surface chemical agent or contains a low surface 
tension, wetting of the liquisolid primary particles is 
improved. Wettability of these systems has been 
confirmed by measurement of contact angles and water 
rising times 
12
. 
GENERAL PROCEDURE FOR PREPARATION 
OF LIQUISOLID COMPACT TABLETS 
1. A drug substance should be initially dissolved or 
suspended in a suitable non-volatile solvent system to 
produce a drug solution or drug suspension of desired 
concentration. 
2. Then a mixture of carrier or different polymers and 
excipients were added to the above liquid medication 
under continuous mixing in a mortar. These amounts of 
the carrier and excipients areenough to maintain 
acceptable flow and compression properties. 
3. To the above binary mixture disintegrant like sodium 
starch glycolate and other reaming additives were added 
according to their application and mixed for a period of 
10 to 20 min. in a mortar. 
4. The final mixture was compressed using the manual 
tableting machine to achieve tablet hardness. 
5. Characterize the final liquisolid granules for 
solubility, dissolution, flowability, compressibility and 
other physicochemical properties 
13
. 
 
 
Figure 2: Schematic Diagram Representing 
Preparation of Liquisolid Compacts 
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COMPONENTS OF LIQUISOLID COMPACT 
FORMULATIONS 
1. Non-volatile Solvent 
Non-volatile Solvent should be Inert, high boiling point, 
ideally water-miscible and not extremely viscous 
organic solvent systems and compatible with having 
ability to solubilise the drug. The non-volatile solvent 
acts as a binding agent within the liquisolid formulation. 
Various non-volatile solvents used in the formulation of 
liquisolid compact. Eg. Polyethylene glycol 200 and 
400, glycerin, polysorbate 80 and propylene glycol. 
2. Disintegrant  
Super disintigrants rises the rate of drug release, water 
solubility and wettability of liquisolid granules. Mostly 
super disintigrants like sodium starch glycolate and cross 
povidone. 
3. Carrier Materials  
Carrier material should be porous material possessing 
adequate absorption properties which contributes in 
liquid absorption. The carrier and coating materials will 
retain only solely bound amounts of liquid and at the 
constant time maintain acceptable flow and compression 
properties therefore, increasing moisture content of 
carrier leads to decreased powder flow ability These 
contain grades of microcrystalline cellulose such as 
avicel PH 102 and avicel PH 200.  
4. Coating Materials  
Coating material should be a material possessing fine 
and extremely surface-assimilative particles that 
contributes in covering the wet carrier particles and 
displaying a dry looking powder by adsorbing any 
excess liquid. Coating material is required to cover the 
surface and maintain the powder flowability34.Coating 
material includes silica (Cab-O-Sil) M520, 35, Aerosil 
20030, Syloid, 244FP 20,35 etc
 14,15
. 
Examples of some drugs that can be incorporated 
into liquisolid systems: 
 Chlorpheniramine 
 Digoxin 
 Nifedipine 
 Clofibrate 
 Gemfibrozil 
 Etoposide 
 Carbamazepine 
 Hydrochlorothiazide 
 Methyclothiazide 
 Spironolactone 
 Hydrocortisone 
 Piroxicam 
 Indomethacin 
 Ibuprofen 
PRE-COMPRESSION STUDIES OF THE 
LIQUISOLID SYSTEM 
Flow Properties of the Liquisolid System: 
The flow properties of the liquisolid systems were 
calculable by determining the angle of repose, Carr’s 
index, and Hausner’s ratio. 
Angle of repose: 
The angle of repose physical mixtures of liquisolid 
compacts were determined by fixed funnel method. The 
accurately weighed physical mixtures of liquisolid 
compacts were taken in a funnel. The height of the 
funnel was adjusted in such how that the tip of the 
funnel simply touches the apex of the heap of the 
powder. The powder was allowed to flow through the 
funnel freely into the surface. The height and diameter 
of the powder cone was measured and angle of repose 
was calculated. 
Tan θ= h/r 
Where, θ is the angle of repose, h is the height, r is the 
radius. 
Values for angle of repose ≤ 300 usually indicate a free 
flowing material and angles ≥ 400 suggest a poorly 
flowing material. 25- 30 showing excellent flow 
properties,31-35 showing good flow properties, 36-40 
showing fair flow properties, 41-45 showing passable 
flow properties. 
Bulk Density: 
The loose bulk density and tapped density were 
determined by using bulk density apparatus. Apparent 
bulk density was determined by pouring the blend into a 
graduated cylinder. The bulk volume (Vb) and weight of 
the powder (M) was firm. The bulk density was 
calculated using the formula:  
Db=M/Vb 
Where, M is the mass of powder 
Vb is bulk volume of powder 
Tapped Density: 
The measuring cylinder containing a known mass of 
blend was tapped for a fixed time. The minimum volume 
(Vt) occupied within the cylinder and therefore the 
weight (M) of the mix was measured. The tapped 
density was calculated using the Formula: 
Dt= M/Vt 
Where, M is the mass of powder 
Vt is tapped volume of powder 
Carr’s Index (%): 
The compressibility index has been proposed as an 
indirect measure of bulk density, size and shape, surface 
area, moisture content and cohesiveness of material 
because all of these ca influence the observed 
compressibility index. The simplest method for 
measurement of free flow of powder is Carr’s Index, a 
indication of the benefit with which a material can be 
induced to flow is given by Carr’s index (CI) which is 
calculated as follows:  
CI (%) = [(Tapped density – Bulk density) / Tapped 
density] x 100 
The value below 15% indicates a powder with 
sometimes offers rise to good flow characteristics, where 
as above 25% indicates poor flow ability.  
Pawar et al                                                                                                                Journal of Drug Delivery & Therapeutics. 2017; 7(4):6-11                                  
ISSN: 2250-1177                                                                              [10]                                                                            CODEN (USA): JDDTAO 
Hausner’s Ratio: 
Hausner’s ratio is an indirect index of ease of powder 
flow. It is calculated by the following formula. 
Hausner’s Ratio=Tapped density (ρt) / Bulk density (ρb) 
Where ρt is tapped density and ρb is bulk density. Lower 
Hausner’s ratio (<1.25) indicates better flow properties 
than higher ones, between 1.25 to 1.5 showing moderate 
flow properties and more than 1.5 poor flow
 16,17
. 
POST COMPRESSION STUDIES OF LIQUI-
SOLID COMPACTS 
Hardness:  
Monsanto hardness tester can be used for the 
determination of the hardness. The tablet to be tested 
was held between a fixed and moving jaw and reading of 
the indicator adjusted to zero. The force applied to the 
edge of the tablet is gradually increased by moving the 
screw knob forward until the tablet breaks. Reading is 
noted down and is expressed in kg/cm. 
 Thickness:  
The crown to crown thickness of tablets is measured by 
Vernier Caliper. It is expressed in mm. the thickness 
variation allowed are ± 5% of the size of the tablet.  
Weight Variation: 
Twenty tablets were randomly selected from each batch 
and individually weighed. The average weight and 
standard deviation three batches were calculated. It 
passes the test for weight variation test if less than two 
of the individual tablet weights deviate from the 
everyday weight by quite than the allowed proportion 
deviation and none deviate by more than twice the 
proportion shown. It was calculated on an electronic 
weighing balance. 
Friability: 
The friability of the tablet can determined using Roche 
Friabilator. It is expressed percentage (%). 10 tablets 
were at first weighed and transferred into the friabilator. 
The friabilator was operated at 25 rpm for 4 minutes. 
The tablets were weighed again. And the % friability 
was calculated as. 
Friability = ([WO – W] /WO) 100  
Where, WO = Initial weight of tablet.  
W = after test weight of tablet. 
Disintegration Test: 
Six tablets were taken randomly from each batch and 
placed in USP disintegration apparatus baskets 
Apparatus was run for 10 minutes and the basket was lift 
from the fluid, observe whether all of the tablets have 
disintegrated. 
In-vitro Release: 
Drug release from liquisolid tablets was determined by 
using dissolution test apparatus United States 
Pharmacopoeia (USP) type II (paddle). 5ml aliquots of 
sample were withdrawn each time at suitable time 
intervals (5, 10, 15, 20, 25, 30, 45 and 60 minutes.) and 
replaced with fresh medium. After withdrawing, samples 
were filtered and analyzed after appropriate dilution by 
appropriate analytical method. The concentration was 
calculated using standard calibration curve. 
Uniformity of Drug content: 
The drug content can be determined by triturating 
sufficient amount of tablets and powder equivalent to 
average weight was added in 100 ml of suitable buffer 
solution. Followed by stirring for 30 min. Dilute suitably 
and the absorbance of resultant solution was measured 
spectrophotometrically 
18
. 
Differential Scanning Calorimetry (DSC) 
Differential Scanning Calorimetry (DSC) is performed 
in order to assess the thermo tropic properties and the 
thermal behaviors of the drug, excipients used in the 
formulation of the liquisolid system. Complete 
disappearance of characteristic peaks of drug indicates 
the formulation of the drug solution in the liquisolid 
powder system, i.e., the drug is molecularly dispersed 
within the liquid matrix 
19
. 
Fourier Transform Infrared Spectroscopy (FTIR)  
These studies are performed to estimate the chemical 
interactions between excipients and drug. If there's the 
presence of characteristic peaks and absence of 
additional peaks in formulation indicates that there are 
not any chemical interactions. 
Powder X-ray Diffraction (PXRD)  
The disappearance of characteristic peaks and holding of 
additional peaks of carriers within the liquisolid 
formulation is observed. It indicates that drug converted 
to amorphous form or to stabilized form 
20
. 
APPLICATIONS OF LIQUISOLID COMPACTS
21
 
 Rapid release rates are obtained in liquisolid 
formulations. 
 Liquisolid compact technology is a powerful tool to 
improve bioavailability of water insoluble drugs. 
Several water insoluble drugs on dissolving in 
different non-volatile solvents have been formulated 
into liquisolid compacts. 
 These can be powerfully used for water insoluble 
solid drugs or liquid lipophilic drugs. 
 Sustained release of drugs which are water soluble 
drugs such as propranolol hydrochloride has been 
obtained by the use of this technique. 
 Solubility and dissolution enhancement. 
 Flowability and compressibility. 
 Designing of controlled release tablets. 
 Application in probiotics. 
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ADVANTAGES OF LIQUISOLID SYSTEMS 
22
 
 A countless number of slightly and very slightly water-
soluble and practically water- insoluble liquid and solid 
drug can be formulated into liquisolid systems using the 
new   formulation-mathematical mode  
 Number of water-insoluble solid drug can be formulated 
into liquisolid systems. 
 This technique is successfully applied for low dose 
water insoluble drug.   
 Lower production cost than that of soft gelatin capsules.   
 Drug dissolution from liquisolid compact is independent 
to the volume of dissolution   media.  
 Maximum of liquid or solid ‘water-insoluble drug’ may 
be formulated into immediate release or sustained 
release ‘Liquisolid compact’ 
 Exhibits enhanced in-vitro and in-vivo drug release as 
compared to commercial counterparts, including soft 
gelatin capsule preparations.   
 Can be used in controlled drug delivery.  
 Increase bioavailability as compared to conventional 
tablets.   
 Drug release can be modified using proper formulation 
ingredients. 
LIMITATIONS 
23
 
 Not applicable for the formulation of high dose 
insoluble drugs.  
 If more amount of carrier is added to produce free 
flowing powder, the tablet weight increases to more 
than one gram which is difficult to swallow. 
 Suitable compression properties might not be achieved 
since throughout compression liquid drug may be 
squeezed out of the liquid-solid tablet resulting in 
tablets of inadequate hardness.  
 Introduction of this method on industrial scale and to 
overcome the problems of mixing small quantities of 
viscous liquid solutions onto large amounts of carrier 
material may not be feasible.  
CONCLUSION  
In conclusion, the liquisolid system is that the new 
technique for the formulation of water insoluble drugs to 
improve their aqueous solubility, absorption still as 
dissolution rate, which leading to improvement of 
bioavailability of drugs as compared to conventional 
directly compressed tablets. Liquisolid formulations were 
designed to contain liquid medications in powdered form. 
The technique is also used hydrophilic carries in liquisolid 
systems. Therefore, increase the wetting properties and 
surface area of drug particles, and hence improve the 
dissolution profiles and might be oral bioavailability of the 
drug. 
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